Showing results (361-370 of 554) with videos related to
Sort By:
Pageof 56
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993M B Atkins, M T Lotze, J P Dutcher, et al.Journal of Oncology|March 1, 2022
Incidence and Durability of SARS-CoV-2 Antibodies in Patients with Cancer and Health Care Workers following the First Wave of the PandemicCatherine Lai, Arnold L Potosky, Colleen McGuire, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 24, 2012
Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2Richard W Joseph, Jeanette E Eckel-Passow, Ruchi Sharma, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2017
Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697)Lisa H Butterfield, Fengmin Zhao, Sandra Lee, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2015
Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697)David H Lawson, Sandra Lee, Fengmin Zhao, et al.Radiology|December 1, 2020
Arterial Spin Labeled Perfusion MRI for the Evaluation of Response to Tyrosine Kinase Inhibition Therapy in Metastatic Renal Cell CarcinomaLeo L Tsai, Rupal S Bhatt, Meaghan F Strob, et al.Journal for Immunotherapy of Cancer|October 2, 2021
PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanomaGeoffrey T Gibney, Jacob Zaemes, Shelly Shand, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2022
Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 TrialBrian I Rini, Javid J Moslehi, Marc Bonaca, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancerKim Margolin, Michael B Atkins, Janice P Dutcher, et al.European Urology|June 26, 2012
BRAF mutations in metanephric adenoma of the kidneyToni K Choueiri, John Cheville, Emanuele Palescandolo, et al.Pageof 56